syndrome, this work provides an expanded view of RASopathy cardiac arrhythmia phenotype as we demonstrate mutant proteins throughout this signaling pathway can also give rise to ectopic and/or MAT.
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| I N TR ODU C TI ON
The RAS/MAPK signaling pathway performs critical cellular differentiation and maintenance functions in a variety of organ systems ( Figure 1 ) (Rauen, 2013; Tidyman & Rauen, 2009) . Activating mutations in the RAS/MAPK signaling pathway result in a family of related disorders termed "RASopathies" that include Costello syndrome (OMIM #218040), Noonan syndrome (#163950), Noonan syndrome with multiple lentigines (formerly known as LEOPARD syndrome) (#151100), and Cardiofaciocutaneous syndrome (#115050). This group of disorders can have overlapping skeletal, dermatologic, musculoskeletal, and neurocognitive features. Additionally, individuals with RASopathies frequently express similar cardiac phenotypes, encompassing structural and electrophysiologic abnormalities. Common cardiac abnormalities seen in RASopathies include hypertrophic cardiomyopathy (HCM), valve abnormalities, particularly pulmonic valve stenosis, and dysplasia, as well as an increased incidence of atrial and ventricular septal defects among others (Lin et al., 2011; Prendiville et al., 2014) . While the frequency and type of structural cardiovascular abnormalities in RASopathies have been detailed elsewhere (Lin et al., 2011; Pandit et al., 2007; Pierpont et al., 2014; Prendiville et al., 2014; Rauen et al., 2010; van Berlo, Maillet, & Molkentin, 2013) , cardiac electrophysiological abnormalities in these syndromes have been less well characterized (Dodo, Gow, Hamilton, & Freedom, 1995) , with the exception of individuals with Costello syndrome who have been described with multifocal atrial tachycardia (MAT). Although much progress has been made in identifying the genetic causes of heritable arrhythmias, the genetic basis of nonreentrant atrial arrhythmias in infants and children is largely unknown. An attempt to identify genes that are known to cause triggered activity, and are not already known to cause channelopathy (long QT syndrome [LQTS] , catecholaminergic polymorphic ventricular tachycardia [CPVT] , or Brugada Syndrome) or familial atrial fibrillation yields a surprisingly small number of genes. Such genes include guanine nucleotide-binding protein inhibiting polypeptide (GNAI2, OMIM #192605); and trans-2,3-enoyl-CoA reductase-like protein (TERCL, OMIM #617242), which appears to regulate two proteins known to cause CPVT, the ryanodine receptor (RYR2, OMIM# 180902) and calsequestrin (CASQ2, OMIM#114251) .
One gene associated with both ectopic and MAT includes troponin I interacting kinase (TNNI3K, OMIM#613932), a kinase that is also thought to affect calcium handling, and is associated with a cardiomyopathy phenotype in some instances (Theis et al., 2014) . The only other two genes associated with these arrhythmias identified in OMIM are those in the RAS/MAPK pathway (HRAS, KRAS, NRAS, OMIM #190020, OMIM #218040).
The purpose of this study is to detail the cardiac electrophysiologic phenotypes and to characterize arrhythmia clinical course including treatment seen in individuals with RASopathies. We demonstrate that nonreentrant atrial tachycardias, MAT and ectopic atrial tachycardia (EAT), can arise from gain-of-function mutations in multiple genes giving rise to RAS/MAPK pathway dysregulation. This represents an expanded description of RASopathy cardiac phenotype as nonreentrant arrhythmia had previously only been reported in Costello syndrome patients. We further show that arrhythmia can occur in the presence or absence of cardiac hypertrophy, suggesting that the atrial arrhythmia seen in these patients is not simply resulting from hypertrophic cardiomyopathy pressure load. These findings provide important clinical information for the diagnosis and management of RASopathy patients, and may provide insights into nonreentrant atrial arrhythmia mechanisms.
| M A TER I A LS A N D M ETH OD S
We retrospectively collected and reviewed the clinical, cardiac, and molecular genetic features of patients with a RASopathy who presented with arrhythmia and/or cardiomyopathy, and were cared for at six institutions (the Children's Hospital of Philadelphia, A.I. du Pont Hospital for Children, Maine Medical Center, Cincinnati Children's Hospital Medical Center, Children's Hospital Colorado, and Sanford Children's Hospital) between 2008 and 2013. Two-dimensional echocardiography was performed using standard pediatric echocardiographic methods and commercially available machines. Segmental anatomy was confirmed and quantitative measures for left ventricular (LV) end diastolic dimension (LVeDD), LV end-systolic dimension (LVeSD), interventricular septal dimension (IVS) were obtained from mmode imaging in the parasternal short axis. These values were normalized using gender, age, and body surface area resulting in a z-score.
Echocardiography images and reports were reviewed to evaluate for evidence of congenital heart defects, hypertrophic cardiomyopathy, and quantitative wall dimensions. Z-score were extracted and displayed in table format. Standard 12 or 15 lead surface electrocardiograms with rhythm strips were obtained from each patient and reviewed to confirm arrhythmia diagnosis. Of the nonreentrant tachycardias, we defined MAT (also sometimes described as chaotic atrial rhythm, CAR) as a tachyarrhythmia with the following characteristics:
(a) multiple (at least three) distinct P-wave morphologies; (b) irregular P-P intervals; (c) isoelectric baseline between P-waves; and (d) ventricular rate >100 beats/min (Bradley, Fischbach, Law, Serwer, & Dick, 2001) . EAT is characterized by (a) a P-wave morphology during tachycardia that is unique from the sinus P-wave, (b) the P wave of the first beat is identical to that of subsequent beats in tachycardia; (c) the cycle length of the first few beats may progressively shorten; (d) atrioventricular block can occur in the presence of continuing atrial arrhythmia;
and (e) ventricular rate >100 beats/min (Bradley et al., 2001; Salerno, Anderson, Sharkey, & Iber, 1987) .
All patients had a clinical and molecular diagnosis of a RASopathy syndrome. Molecular genetic testing was performed as clinically indicated at the commercial molecular diagnostic labs routinely used by each patient's institution. (Pandit et al., 2007; Rauen, 2013; Rodriguez-Viciana et al., 2006; Tartaglia, Cotter, Zampino, Gelb, & Rauen, 2003; Tidyman & Rauen, 2009; Wu et al., 2011) , with the exception of Noonan syndrome with multiple lentigines in which there are dominant negative effects from loss-of-function mutations. Each confirmed mutation is listed in Table 1 . (Table 1) .
| R E SU LTS

| Noncardiac clinical features
Postnatally, hyper-pigmented macules and dysmorphic craniofacial features prompted molecular testing with increased suspicion for RASopathy. Additional features suggesting RASopathies included down slanted palpebral fissures, wide nasal root with flat bridge, low set dysmorphic ears, and coarse facial features.
| Cardiac clinical features
Arrhythmias were documented from the fetal period to as late as 4 years of age (mean 222 6 95 days) ( Table 1) Figure   2b , which is characteristic of EAT. Quantitative echocardiographic data were available for eleven patients ( 
| Arrhythmia treatment
Patients presenting in the neonatal period often had mild hemodynamic compromise and poor feeding over time prior to restoration of sinus rhythm. Initial medical therapies included propranolol in 10 patients.
Treatment with propranolol alone and/or with digoxin failed to maintain sinus rhythm in all but one patient (Table 1) . Flecainide alone or in combination with propranolol was the most common chronic anti-arrhythmic treatment chosen. Amiodarone alone was used successfully for two patients, although one patient subsequently transitioned to propranolol and verapamil due to amiodarone toxicity. Anti-arrhythmic agents were successfully weaned in all patients, except for one who died from complications of a rhabdomyosarcoma and a second who underwent cardiac transplantation, in part because of functional hemodynamic instability that was compounded by rhythm disturbance despite flecainide treatment. In the 10 patients whose clinical arrhythmias resolved, medications were discontinued at a mean age of 28.0 months (range 6.5-49 months).
A third child from our cohort died from complications of cardiac surgery (septal myomectomy). This child's arrhythmia resolved prior to surgery, so this case was not considered an anti-arrhythmic treatment failure. A 4-month-old child with cellulitis apparently died of complications of systemic infection, unrelated to arrhythmia.
| D ISC USSION
This multi-institutional case series illustrates an association between mutations in RAS/MAPK signaling pathway genes and nonreentrant atrial tachycardia (MAT and EAT). Importantly, rhythm disturbances occurred both in the presence and absence of cardiac hypertrophy. We observed predominantly nonreentrant atrial tachycardia in our cohort (i.e., EAT and MAT, which is also known as CAT). Reportedly, 84% of atrial arrhythmias in children arise from reentrant circuits involving accessory pathways (Ko, JK, BJ, Strasburger, and Benson DW jr., 1992) . In contrast, in our cohort, we observed nonreentrant atrial arrhythmias, which had previously been identified only in Costello syndrome patients (Lin et al., 2011) .
Distinguishing between reentrant and nonreentrant arrhythmias can be critically important as therapies and prognoses differ greatly between these two entities. Propranolol and digoxin continue to be the preferred first line treatment for reentrant arrhythmias. However, we found that infants with RASopathies and atrial tachycardia can be difficult to manage, partially because propranolol and digoxin fail to convert or maintain sinus rhythm in patients with MAT and EAT. By contrast, in this cohort, effective medications included flecainide alone, flecainide in combination with propranolol, or amiodarone alone. While propranolol can be used to treat EAT effectively in other patient populations, it is not immediately clear why this drug is less effective in this subgroup of patients. Importantly, arrhythmia resolved or was well-controlled in all but two cases. The former were successfully weaned off antiarrhythmic medications after a period ranging from 6.5 to 49 months.
The latter group included a 4 months old boy who was found pulseless and unresponsive during inpatient cellulitis treatment and died from an unclear etiology and another patient who underwent cardiac transplantation. This second patient had poorly tolerated break-through tachycardia in the context of worsening left ventricular outflow obstruction.
While an atrial arrhythmia episode would not be predicted to cause catastrophic hemodynamic compromise, we cannot exclude the possibility that atrial arrhythmia complicated this boy's death.
While flecainide, a sodium channel blocker, has been used successfully to treat ectopic or MAT for over 20 years (Houyel, Fournier, & Davignon, 1990) , the mechanism of its efficacy is not immediately obvious and remains controversial (Bannister et al., 2015; Hilliard et al., 2010; Smith & Macquaide, 2015; Watanabe et al., 2009 ). Previous studies suggested that MAT and EAT result from disrupted calcium homeostasis leading to triggered activity (Levine, Michael, & Guarnieri, 1985; Marchlinski & Miller, 1985) . Flecainide, by contrast, is traditionally classified as a sodium channel blocker (Vaughan Williams, 1975) , and sodium channel blockers would not be expected to affect calcium homeostasis directly. Importantly, it has been argued that flecainide diminishes calcium release from the sarcoplasmic reticulum through ryanodine receptors in addition to its direct inhibitory action on sodium channels (Bannister et al., 2015; Mehra, Imtiaz, van Helden, Knollmann, & Laver, 2014; Smith & Macquaide, 2015; Watanabe et al., 2009 In addition to increased arrhythmogenesis, disordered calcium handling can contribute to cardiomyopathy and heart failure (Anastasaki, Estep, Marais, Rauen, & Patton, 2009; Lan et al., 2013) . Incessant atrial arrhythmias may cause cardiomyopathy and diminished cardiovascular function. Conversely, arrhythmias may be secondary to the pressure load conferred by a cardiomyopathy. Finally, the presence of cardiomyopathy prior to arrhythmia might suggest that nonreentrant atrial tachycardia is secondary to elevated end-diastolic pressure subsequent to cardiomyopathy (pressure load). In this retrospective case series, we found that 4 (36%) of 11 patients presenting with nonreentrant atrial tachycardia had no evidence of cardiomyopathy as indicated by increased wall thickness. Thus, at least some atrial tachycardia in our cohort did not arise secondary to pressure overload, again suggesting disordered calcium release arises as a result of some other mechanism.
Hypertrophic cardiomyopathy is defined by abnormal wall thickness (Elliott & McKenna, 2004; Maron, 2006; McNally, Barefield, & Puckelwartz, 2015) . Seven (64%) of our 11 patients demonstrated car- suggests that these patients have elevated intracellular calcium concentrations since there is a strong dependence between intracellular calcium concentration and myocyte contraction force (Kentish, ter Keurs, Ricciardi, Bucx, & Noble, 1986; Sun & Irving, 2010) .
Thus, several observations suggest that RASopathy patients exhibit calcium dysregulation that can give rise to cardiomyopathy and/or atrial tachycardia. First, RASopathy patients demonstrate MAT and EAT thought to be initiated by triggered activity (Bradley et al., 2001; Marchlinski & Miller, 1985; McCord & Borzak, 1998 The current study is limited by its small patient numbers. Given the relatively rare occurrence of non-Noonan syndrome RASopathies, we pooled patients from a multi-institutional network. Although Cardiofaciocutaneous syndrome was not represented in this series, it is likely that nonreentrant tachycardia will be observed. Further work to verify our observations in a larger cohort should be performed, ideally in a prospective manner. Additional studies using animal models or patientspecific expression systems should be used to test the hypotheses raised here. This would be an important first step in deepening our understanding of RASopathy cardiac disease mechanisms and could ultimately lead to the identification and development of novel therapeutics for patients with RASopathies.
In conclusion, we report that patients with RAS/MAPK pathway mutations have nonreentrant atrial tachycardia that is poorly treated by propranolol or digoxin (typical first-line SVT treatments), but responds well to flecainide or amiodarone alone or in concert with propranolol.
Atrial tachycardia in RASopathy patients occurred in the presence and absence of hypertrophic cardiomyopathy. Those patients with nonreentrant tachycardia without hypertrophic cardiomyopathy frequently demonstrated hyper-dynamic function as evidenced by increased shortening fraction, suggesting that they possessed increased intracellular calcium.
Nonreentrant tachycardia resolved in 9 of 11 patients. In addition to providing insights that will aid management of patients with a RASopathy, the clinical findings here suggest the hypothesis that activating RAS/ MAPK pathway mutations result in intracellular calcium dysregulation that leads to either arrhythmia, cardiac hypertrophy, or both. There is a need for additional investigation and longitudinal study in this patient population to define evidence based guidelines for cardiac surveillance, but, in the interim, contributing authors have suggested collaborative expert opinion consensus statements may also be useful. Toward this end, we would suggest raising suspicion for arrhythmia and cardiomyopathy in neonatal RASopathy patients. Respiratory distress, diminished feeding tolerance, or unexplained irritability should suggest cardiac evaluation, including ECG, echocardiogram and 24 hr ambulatory ECG monitoring. In addition to typical signs and symptoms of arrhythmia or cardiomyopathy, evidence of hyperdynamic cardiac function seen on echocardiogram should also raise suspicion for arrhythmia, cardiomyopathy or nascent cardiomyopathy as this was present in some study patients with arrhythmia prior to overt chamber dimension abnormal-
ities. This case series should increase awareness among pediatric cardiologists and geneticists about these increasingly recognized syndromes and provide clinical information assisting the diagnosis and management of cardiac disease, and, ultimately promote understanding of the molecular mechanisms underlying these diseases.
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